• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

    100.93 +1.68 (+1.69%)
    Streaming Delayed Price Updated: 2:02 PM EDT, Aug 3, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 344,810
    Open 100.39
    Bid (Size) 100.72 (100)
    Ask (Size) 101.13 (100)
    Prev. Close 99.25
    Today's Range 97.99 - 101.39
    52wk Range 74.50 - 122.20
    Shares Outstanding 66,684,077
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -3.9%
    -3.9%
    1 Month
    -9.6%
    -9.6%
    3 Month
    +17.9%
    +17.9%
    6 Month
    -7.4%
    -7.4%
    1 Year
    +11.8%
    +11.8%

    More News

    Read More
    News headline image
    Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates ↗
    Via Chartmill
    News headline image
    Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    My Top 3 Stocks to Buy in May ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results ↗
    Via Benzinga
    News headline image
    Rhythm (RYTM) Q1 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday ↗
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    Via MarketMinute
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Rhythm Pharmaceuticals Announces Changes to Board of Directors
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Is This Weight Loss Drug Stock a Buy After a New Approval? ↗
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
    Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
    What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 100.93
    When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 08/03/26 02:02 PM ET
    What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 6.73B
    How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
    Rhythm Pharmaceuticals, Inc. - Common Stock has 7B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.